NCT07140484View on ClinicalTrials.gov

Sotatercept in Pulmonary Arterial Hypertension

PHASE4RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2030

Conditions
Pulmonary Artery Hypertension
Interventions
DRUG

Sotatercept

0.7mg/kg

Trial Locations (1)

T6G2R3

RECRUITING

Clinical Physiology Laboratory, Edmonton

All Listed Sponsors
collaborator

Merck Canada Inc.

INDUSTRY

collaborator

Alberta Health services

OTHER

lead

University of Alberta

OTHER